Rothnie, KJ; Quint, JK (2016) Chronic obstructive pulmonary disease and acute myocardial infarction: effects on presentation, management, and outcomes. European heart journal Quality of care & clinical outcomes, 2 (2). pp. 81-90. ISSN 2058-5225 DOI: https://doi.org/10.1093/ehjqcco/qcw005

Downloaded from: http://researchonline.lshtm.ac.uk/4646762/

DOI: 10.1093/ehjqcco/qcw005

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
Chronic obstructive pulmonary disease and acute myocardial infarction: effects on presentation, management, and outcomes

Kieran J. Rothnie1,2* and Jennifer K. Quint1,2

1Respiratory Epidemiology, Occupational Medicine and Public Health, National Heart and Lung Institute, Imperial College London, Emmanuel Kaye Building, London SW3 6LR, UK; and 2Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK

Received 11 December 2015; online publish-ahead-of-print 4 February 2016

Cardiovascular disease is a common cause of death in patients with chronic obstructive pulmonary disease (COPD) and is a key target for improving outcomes. However, there are concerns that patients with COPD may not have enjoyed the same mortality reductions from acute myocardial infarction (AMI) in recent decades as the general population. This has raised questions about differences in presentation, management and outcomes in COPD patients compared to non-COPD patients. The evidence points to an increased risk of death after AMI in patients with COPD, but it is unclear to what extent this is attributable to COPD itself or to modifiable factors including under-treatment with guideline-recommended interventions and drugs. We review the evidence for differences between COPD and non-COPD patients in terms of the presentation of AMI, its treatment, and outcomes both in hospital and in the longer term.

Keywords
Chronic obstructive pulmonary disease ● Management of acute coronary syndromes ● Co-morbidity ● Mortality ● Epidemiology

Background
Recent decades have seen substantial reductions in the incidence of acute myocardial infarction (AMI) and its mortality.1,2 Much of the decrease in incidence has been attributable to a decrease in ST-elevation myocardial infarction (STEMI). Rates of non-ST elevation myocardial infarction (NSTEMI) have not decreased and may be increasing perhaps due to population ageing or clinical awareness.3 Patients with NSTEMI tend to be older and have more co-morbidities than patients with STEMI, increasing their risk of death in the longer term.4 Much of the decrease in AMI mortality has been attributed to improvements in care, but it is not clear if this has been optimized for all patient groups.5 Some high-risk groups have received particular attention and in diabetes, for example, ischaemic presentations may be atypical and thresholds for investigation and treatment are set at a lower level compared with non-diabetic patients.6 However, other groups have received less attention and chronic obstructive pulmonary disease (COPD), in particular, has been under-studied in patients with AMI despite it being common, affecting ~1.5% of the European population, although the true prevalence may be as high as 10% as many patients remain undiagnosed.7 In the developed world, the most important risk factor for COPD is tobacco smoking; other risk factors include increased age, indoor and outdoor pollution, poor nutrition, and low socio-economic status.8

Chronic obstructive pulmonary disease is associated with an increased risk of many other diseases, which are thought to be due, in part, to ‘spill over’ of inflammation in the lung to the systemic circulation9 (Figure 1). Cardiovascular disease is perhaps the most common co-morbidity and people with COPD, particularly in younger age groups, are at increased risk of AMI, independent of smoking status.10,11 Inflammation, endothelial dysfunction, and increased arterial stiffness, in addition to shared risk factors, are all thought to contribute to cardiovascular risk in COPD.12 Most people with COPD do not die from respiratory diseases,13 with cardiovascular disease being a major cause, accounting for ~30% of all deaths.14

This article will review contemporary literature on how COPD affects the presentation, management, and outcomes of AMI and how these may be interrelated.

* Corresponding author. Tel: +44 20 7594 8824; Email: k.rothnie@imperial.ac.uk

© The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Presentation of acute myocardial infarction

The prevalence of previously diagnosed COPD among patients presenting to hospital with AMI has been estimated as 10–17%. The true prevalence, including patients with undiagnosed COPD, may be significantly higher. Several studies have reported that patients with COPD are less likely to present with typical chest pain than patients without COPD, and are more likely to present with breathlessness, atypical chest pain, and palpitations. They are also more likely than patients without COPD to present with NSTEMI than STEMI and to have lower diagnostic biomarker levels, including troponin and creatine kinase. In one study, COPD has been associated with late presentation 12 h after onset of symptoms.

Recognition and management of acute myocardial infarction

One possible consequence of the differences in presentation of AMI in COPD is that its recognition is delayed or missed altogether. Around 8% of patients admitted to hospital with an acute exacerbation of COPD meet the Universal Definition for Myocardial Infarction, but it is unclear whether this represents type 2 AMI triggered by the exacerbation or type 2 AMI misdiagnosed as the exacerbation. At least 33% of patients admitted with COPD and to have lower diagnostic biomarker levels, including troponin and creatine kinase. In one study, COPD has been associated with late presentation >12 h after onset of symptoms.

Recent studies conducted in Sweden and the UK have shown that patients with COPD are less likely than patients without COPD to receive primary percutaneous intervention (pPCI) or other reperfusion strategies after a STEMI, confirming earlier US studies. A more recent US study, however, found no difference in rates of pPCI between patients with and without COPD, suggesting a change in practice and emphasizing the importance of observational data for identifying inequalities in patient management.

NSTEMI guidelines recommend in-hospital cardiac catheterization within 72 h for patients with a ≥3% predicted risk of death at 6 months. Percutaneous intervention, as indicated, improves outcomes, patients at highest risk having most to gain from the intervention. Several studies have shown that patients with COPD who present with NSTEMI are less likely to receive in-hospital angiography compared with patients without COPD, despite being at higher risk. A potential explanation for this difference is that COPD patients are older and more likely to be deemed sicker or frailer than non-COPD patients, and not appropriate for more aggressive intervention. However, when comparisons are made after exclusion of patients inappropriate for angiography due, for example, to advanced cancer or dementia, findings of under-treatment are unchanged and rates of angiography remain lower in patients with than without COPD.
Under-treatment of patients with COPD presenting with AMI extends beyond the acute phase. Contemporary guideline recommendations, based on randomized clinical trials, are for secondary prevention treatment with a β-blocker; an ACE inhibitor or angiotensin receptor blocker, a statin, and dual antiplatelet therapy (aspirin indefinitely and P2Y12 Receptor antagonist for 1 year) for all patients with AMI unless there are clear contraindications.2425 It has been the widely held belief that COPD contraindicates treatment with β-blockers because of the potential risk of bronchospasm caused by unopposed activation of α1 adrenergic receptors that result in smooth muscle constriction. However, many studies have shown that cardioselective β-blockers that are primarily active at cardiac β1 receptors, not bronchial β2 receptors, are not associated with a change in FEV₁ or an increase in exacerbations of COPD.26 Despite this, β-blockers continue to be underused in patients with COPD who are less likely than patients without COPD to receive a prescription after AMI.16–18,21

The under-treatment of patients with COPD extends to other secondary prevention drugs, all of which, with the exception of P2Y₁₂ receptor antagonists, tend to be prescribed less commonly in patients with COPD, although the differences are less marked compared with β-blockers.16–21 Findings from studies that have investigated differences in treatment between COPD and non-COPD patients after AMI are summarized in Table 1. Interestingly, differences in management between COPD and non-COPD patients are not apparent in all settings and appear to have changed over time. As previously mentioned, differences in rates of pPCI between patients with and without COPD appear to have narrowed over time in the USA,20 where prescription of β-blockers to patients with COPD has increased unlike in Europe.6–18 These differences between countries suggest two things: that differences in treatment between COPD and non-COPD patients do represent under-treatment, and that change is possible.

### Outcomes after myocardial infarction in people with chronic obstructive pulmonary disease

#### All-cause mortality

Studies in a variety of settings have demonstrated an increased risk of death during follow-up after AMI for patients with COPD, but whether this applies to in-hospital mortality is less certain, some studies reporting increased mortality16,17,20,21,29–31 and others finding no difference15,32 compared with patients without COPD. The evidence has now been appraised in a systematic review and meta-analysis,11 which concluded that after pooling maximally adjusted estimates from several studies, there is only weak evidence for a difference in in-hospital mortality for patients with COPD (OR 1.13, 95% CI 0.97–1.31) but strong evidence for an increased risk of death during follow-up (HR 1.26, 95% CI 1.13–1.40) (Figure 2). However, effects were heterogeneous between studies perhaps because of the international differences in treatment of AMI between patients with and without COPD. If some of the increased risk of death associated with COPD is due to these treatment differences, this is likely to have contributed to the heterogeneous outcomes identified in the systematic review.

The effect of COPD on risk of death following AMI is modified by mode of presentation, a recent UK study reporting that the adjusted odds of in-hospital and 6-month mortality were higher for NSTEMI [(OR 1.40, 95% CI 1.30–1.52) and (OR 1.63, 95% CI 1.56–1.70)] compared with STEMI [(OR 1.27, 95% CI 1.16–1.39) and (OR 1.43, 95% CI 1.29–1.58)].18 Similar findings have been reported in a US study.20 The effect of COPD on risk after AMI appears to be greater in younger than in older patients (Figure 3), suggesting that the ‘excess’ risk of death attributable to COPD, is clustered in younger patients.18 Dziewierz et al.30 made a similar observation, reporting that COPD was associated with an increased mortality risk after AMI only in patients aged <75. The increased AMI mortality estimates in studies that have compared patients with and without COPD are likely to be underestimate based on the atypical presentations that characterize these patients, a proportion of whom, no doubt, escape diagnosis altogether. Further contribution to the underestimation of risk in these patients is the absence of data on pre-hospital mortality, all existing studies being confined to patients admitted to hospital.

#### Other outcomes

Outcome analyses after AMI in patients with COPD show that the risk of other endpoints, apart from mortality, may also be increased. This applies particularly to heart failure both in the acute phase and after discharge from hospital. Thus, Stefan et al.17 found that after adjusting for confounders, people with COPD were more likely to experience acute heart failure (OR 1.59, 95% CI 1.37–1.83), compared with patients without COPD, but not atrial fibrillation, cardiogenic shock, or stroke. Similar findings have been reported in unadjusted analyses.15,20 Studies of longer-term complications of AMI in patients with COPD confirm that the increased risk of heart failure compared with patients without COPD extends to the chronic phase after discharge from hospital, Andell et al. reporting a hazard ratio of 1.35 (95% CI 1.24–1.47) during the first year.16 Findings were similar in another study that included patients with heart failure or left ventricular systolic dysfunction, and reported a hazard ratio for admission with heart failure of 1.19 (95% CI 1.05–1.34) among patients with COPD during the first 3 years after AMI.33 In the same study, the hazard of sudden death was also higher in patients with COPD (HR 1.26, 95% CI 1.03–1.53), although whether this applies in less selected populations is unclear. Certainly, there is no convincing evidence that patients with COPD are at higher risk of recurrent AMI, stroke, angina, or major bleeds compared with non-COPD patients.16,19,33

### Are differences in recognition and management associated with differences in outcomes?

A key question that arises from the tendency of patients with COPD to present atypically and receive under-treatment of AMI is the extent to which this might explain their adverse outcomes, particularly their heightened risk of death and heart failure compared with patients without COPD.

The association of atypical presentation of AMI with adverse outcomes has been previously reported.34,35 Patients who present atypically are less likely to receive guideline-recommended reperfusion therapy or invasive management and are less likely to receive β-blockers, statins, or antiplatelet therapy on discharge from hospital.16 The tendency of patients with COPD to present with atypical symptoms is, therefore, important because delayed diagnosis of...
| Study            | Design and setting                                             | Population                                                                 | Differences in management                                                                 |
|------------------|----------------------------------------------------------------|---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| Andell et al. 2014<sup>16</sup> | Cohort study within the Swedish SWEDEHEART registry between 2005 and 2010 | Consecutive patients admitted to Swedish coronary care units. COPD diagnosed through linkage to the Swedish National Patient Registry | **In-hospital management**<br>Percutaneous coronary intervention<br>COPD: 37.7%, Non-COPD: 55.7%, P < 0.001<br>Coronary angiography<br>COPD: 72.5%, Non-COPD: 55.4%, P < 0.001 |
|                  |                                                                |                                                                           | Discharge medicines<br>ACE inhibitors<br>COPD: 50.6%, Non-COPD: 55.5%, P < 0.001<br>Angiotensin receptor blockers<br>COPD: 12.6%, Non-COPD: 11.1%, P = 0.001<br>Aspirin<br>COPD: 85.5%, Non-COPD: 90.1%, P < 0.001<br>β-Blockers<br>COPD: 77.7%, Non-COPD: 86.1%, P < 0.001<br>Statin<br>COPD: 68.4%, Non-COPD: 79.2%, P < 0.001<br>P2Y12 inhibitor<br>COPD: 62.5%, Non-COPD: 72.2%, P < 0.001 |
| Bursi et al. 2010<sup>21</sup> | Cohort study in Olmsted County, MN from 1979 to 2007             | 3438 local residents in Olmsted County. ICD-10 codes used to ascertain COPD | **In-hospital management**<br>Reperfusion<br>COPD: 41%, Non-COPD: 52%, P < 0.01<br>Angiography in-hospital<br>COPD: 51%, Non-COPD: 59%, P < 0.01 |
|                  |                                                                |                                                                           | Discharge medicines<br>ACE inhibitor<br>COPD: 37%, Non-COPD: 29%, P < 0.01<br>β-Blocker<br>COPD: 47%, Non-COPD: 61%, P < 0.01<br>Diuretic<br>COPD: 34%, Non-COPD: 23%, P < 0.01<br>Statin<br>COPD: 29%, Non-COPD: 30%, P = 0.61 |

*Continued*
| Study | Design and setting | Population | Differences in management |
|-------|--------------------|------------|--------------------------|
| Enriquez et al. 2013<sup>29</sup> | Cross-sectional study of National Cardiovascular Data Registry in the USA between January 2008 and December 2010 | 158 890 patients with an acute MI. Chronic obstructive pulmonary disease was ascertained from history of COPD or were using long-term inhaled or oral β-agonists, inhaled anti-inflammatory agents, leukotriene receptor antagonists, or inhaled steroids | STEMsis In-hospital management<br>Primary percutaneous coronary intervention<br>COPD: 83.1%<br>Non-COPD: 85.4%<br><br>P < 0.001<br><br>Overall reperfusion<br>COPD: 92.8%<br>Non-COPD: 94.3%<br>P < 0.001<br><br>Discharge medicines<br>Aspirin<br>COPD: 97.8%<br>Non-COPD: 98.7%<br>P < 0.001<br><br>β-Blocker<br>COPD: 89.4%<br>Non-COPD: 93.1%<br>P < 0.001<br><br>ACE inhibitor or angiotensin receptor blocker<br>COPD: 78.0%<br>Non-COPD: 78.4%<br><br>P = 'not statistically significant'<br><br>Statin<br>COPD: 92.9%<br>Non-COPD: 94.7%<br>P < 0.001<br><br>P2Y12 inhibitor<br>COPD: 79.6%<br>Non-COPD: 86.6%<br>P < 0.001<br><br>NSTEMIs In-hospital management<br>Cardiac catheterization<br>COPD: 69.9%<br>Non-COPD: 81.2%<br>P < 0.001<br><br>Percutaneous coronary intervention within 48 hours<br>COPD: 37.2%<br>Non-COPD: 48.9%<br>P < 0.001<br><br>Discharge medicines<br>Aspirin<br>COPD: 95.9%<br>Non-COPD: 97.3%<br>P < 0.001<br><br>β-Blocker<br>COPD: 85.5%<br>Non-COPD: 90.5%<br>P < 0.001<br><br>ACE inhibitor or angiotensin receptor blocker<br>COPD: 69.6%<br>Non-COPD: 69.6%<br>P = 'not statistically significant'<br><br>Statin<br>COPD: 85.9%<br>Non-COPD: 89.5%<br>P < 0.001<br><br>P2Y12 inhibitor<br>COPD: 65.5%<br>Non-COPD: 71.6%<br>P < 0.001 |
| Study | Design and setting | Population | Differences in management |
|-------|--------------------|------------|--------------------------|
| Rothnie et al. 2015<sup>18</sup> | All UK patients admitted to hospital in the MINAP registry between 2003 and 2013 | 300 161 patients with a first MI | STEMI In-hospital management  
Primary PCI  
OR 0.87 (95% CI 0.83–0.92)<sup>a</sup>  
Discharge medicines  
Aspirin  
OR 0.90 (95% CI 0.85–0.94)<sup>a</sup>  
β-Blocker  
OR 0.26 (95% CI 0.25–0.27)<sup>a</sup>  
ACE inhibitor or angiotensin receptor blocker  
OR 0.89 (95% CI 0.85–0.93)<sup>a</sup>  
Statin  
OR 0.91 (95% CI 0.86–0.95)<sup>a</sup>  
P2Y12 inhibitor  
OR 0.98 (95% CI 0.94–1.03)<sup>a</sup> | NSTEMI In-hospital management  
Angiography in-hospital  
OR 0.69 (95% CI 0.66–0.71)<sup>a</sup>  
Discharge medicines  
Aspirin  
OR 0.91 (95% CI 0.88–0.94)<sup>a</sup>  
β-Blocker  
OR 0.25 (95% CI 0.24–0.25)<sup>a</sup>  
ACE inhibitor or angiotensin receptor blocker  
OR 0.94 (95% CI 0.91–0.97)<sup>a</sup>  
Statin  
OR 0.93 (95% CI 0.90–0.96)<sup>a</sup>  
P2Y12 inhibitor  
OR 0.97 (95% CI 0.94–1.01)<sup>a</sup> |
| Salisbury et al. 2007<sup>19</sup> | Cohort study in 19 centres in the USA between 2003 and 2004 | 2481 MI patients in PREMIER study restricted to patients discharged alive after MI | Cardiac catheterization  
COPD: 45.7%  
Non-COPD: 41.2%  
P = 0.094  
Percutaneous coronary intervention  
COPD: 50.9%  
Non-COPD: 62.9%  
P < 0.001  
Discharge medicines  
Aspirin  
COPD: 87.8%  
Non-COPD: 94.5%  
P < 0.001  
β-Blocker  
COPD: 86.2%  
Non-COPD: 92.6%  
P < 0.001 |  
In-hospital management  
Cardiac catheterization  
OR 0.56 (95% CI 0.48–0.65)<sup>b</sup>  
Percutaneous coronary intervention  
OR 0.64 (95% CI 0.54–0.77)<sup>b</sup>  
Discharge medicines  
β-Blocker  
OR 0.44 (95% CI 0.35–0.50)<sup>b</sup>  
Anticoagulant  
OR 0.81 (95% CI 0.69–0.95)<sup>b</sup>  
Statin  
OR 0.70 (95% CI 0.60–0.82)<sup>b</sup>  
Calcium channel blocker  
OR 1.31 (95% CI 1.13–1.52)<sup>b</sup> |
| Stefan et al. 2012<sup>17</sup> | Cohort study of patients hospitalized with acute MI at greater Worcester, MA between 1997 and 2007 | 6290 patients hospitalized with acute MI in greater Worcester, MA medical centres | Cardiac catheterization  
OR 0.56 (95% CI 0.48–0.65)<sup>b</sup>  
Percutaneous coronary intervention  
OR 0.64 (95% CI 0.54–0.77)<sup>b</sup>  
Discharge medicines  
β-Blocker  
OR 0.44 (95% CI 0.35–0.50)<sup>b</sup>  
Anticoagulant  
OR 0.81 (95% CI 0.69–0.95)<sup>b</sup>  
Statin  
OR 0.70 (95% CI 0.60–0.82)<sup>b</sup>  
Calcium channel blocker  
OR 1.31 (95% CI 1.13–1.52)<sup>b</sup> |  
In-hospital management  
Cardiac catheterization  
OR 0.56 (95% CI 0.48–0.65)<sup>b</sup>  
Percutaneous coronary intervention  
OR 0.64 (95% CI 0.54–0.77)<sup>b</sup>  
Discharge medicines  
β-Blocker  
OR 0.44 (95% CI 0.35–0.50)<sup>b</sup>  
Anticoagulant  
OR 0.81 (95% CI 0.69–0.95)<sup>b</sup>  
Statin  
OR 0.70 (95% CI 0.60–0.82)<sup>b</sup>  
Calcium channel blocker  
OR 1.31 (95% CI 1.13–1.52)<sup>b</sup> |

<sup>a</sup>All ORs compared COPD with non-COPD patients and are adjusted for age, sex, smoking status, and co-morbidities.

<sup>b</sup>ORs compare COPD with non-COPD patients and are adjusted for age, sex, year, cardiovascular disease history, renal failure, length of stay, and type of MI (STEMI or NSTEMI).
AMI and its under-treatment with reperfusion therapy and secondary prevention drugs has now been shown to explain some of the excess mortality for patients with COPD. Similar findings have been reported by Andell et al. who found that hazard ratios for mortality in COPD patients fell from 1.32 (95% CI 1.24–1.40) to 1.14 (95% CI 1.07–1.21) following adjustment for in-hospital and discharge treatment. These findings point strongly to delayed diagnosis of AMI and its under-treatment as being important mediators of the adverse outcomes for patients with COPD. They also suggest that differences in treatment between countries may be a plausible reason for heterogeneity in the effects of COPD on risk of death.

In considering delayed diagnosis of AMI and its under-treatment as causes of excess mortality, potential direct effects of COPD should not be overlooked (Figure 4). Chronic obstructive pulmonary disease severity, defined by degree of airflow obstruction, appears to be a risk factor for AMI, but lung function data are unavailable in national AMI registries and it is unclear if it is also a risk factor for outcomes after AMI. Exacerbations of COPD, however, and the associated systemic inflammation, are important drivers of mortality, but whether ‘frequent exacerbators’ are at heightened risk of death after AMI is uncertain. There is greater certainty about the risks associated with smoking that is often responsible for COPD and is also a major risk factor for death and recurrent coronary events after AMI. Indeed, quitting smoking after AMI is one of the most effective preventive strategies, but in heavily dependent COPD patients may be hard to achieve. Smoking cessation pharmacotherapy is underused, and although it may be less effective after AMI, the excess mortality in patients with COPD identifies them as a group that needs targeting.

The under-treatment of AMI in patients with COPD is important because it is potentially modifiable, and provides a means of narrowing the mortality gap between patients without COPD. Although under-treatment can be identified across the management spectrum, it is β-blockers that stand out as the drugs that clinicians often avoid for fear of exacerbating airways obstruction, and this despite there being clear evidence that cardio-selective agents are safe for COPD patients with AMI and also effective for secondary prevention. Thus, Quint et al. conducted a propensity matched cohort study in COPD patients with AMI and showed that patients started on a β-blocker during hospital admission had significantly better
survival than patients not prescribed a β-blocker (HR 0.50, 95% CI 0.36–0.69). Similar results have been reported for a heart failure population with AMI in which COPD did not appear to modify the effect of β-blockers on mortality. The continuing reluctance of clinicians to prescribe β-blockers to COPD patients needs addressing because it may drive much of the increased risk of heart failure and death in the months and years following AMI.

Other potential contributors to the risk management paradox that characterizes AMI patients with COPD include the poor performance of risk algorithms and therapeutic nihilism. Thus, the GRACE score appears to perform less well in patients with COPD, but whether this makes a significant contribution to under-treatment seems unlikely because COPD patients with the same GRACE score as non-COPD patients remain less likely to receive guideline-recommended investigation and treatment. Potentially more important is therapeutic nihilism whereby COPD patients are seen as too old and frail to make interventional management and secondary prevention worthwhile, even though cardiovascular disease is a leading cause of death in patients with COPD and many of the excess deaths are in younger patients.

**Conclusions**

Chronic obstructive pulmonary disease increases the risk of heart failure and death after AMI, particularly in the months after discharge from hospital. Effects are greater in younger patients and those with NSTEMI. Although direct effects of COPD likely contribute to the increased risk, delays in diagnosis and under-treatment are also important. It is the under-treatment of these patients, particularly with β-blockers, that provides the most modifiable target for reducing mortality. Further research is needed to investigate the extent and impact of missed AMI diagnosis in patients with COPD. Researchers should also focus on investigating how AMI risk scores function in COPD and how they should be used to guide treatment.

**Funding**

This work was supported by a Medical Research Council Industry Collaboration Agreement (G0902135). Funding to pay the Open Access publication charges for this article was provided by Imperial College London.

**Conflict of interest**: J.K.Q. reports grants from Medical Research Council and GSK during the conduct of the study; grants from Medical Research Council, BLF, Wellcome Trust, and the Chartered Society of Physiotherapy, and personal fees from AZ and GSK, outside the submitted work.

**References**

1. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. *N Engl J Med* 2010;362:2155–2165.

2. Alzuhaini KS, Segall P, Ravilde J, Gislason G, Kaber L, Torp-Pedersen C. Incidence and outcome of first myocardial infarction according to gender and age in...
Denmark over a 35-year period (1978–2012). Eur Heart J Qual Care Clin Outcomes 2015;4:72–78.

3. McManus DD, Gore J, Yarzebski J, Spencer F, Lessard D, Goldberg RJ. Recent trends in the incidence, treatment, and outcomes of patients with ST and non-ST-segment acute myocardial infarction. Am J Med 2011;124:40–47.

4. Schmidt M, Jacobsen JB, Lash TL, Bakker HE, Sørensen HT. 25 year trends in first time hospitalization for acute myocardial infarction, subsequent short and long-term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. BMJ 2012;344:e356.

5. Smolina K, Wright FL, Eyre M, Goldacre MJ. Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ 2012;344:e005996.

6. Junghans C, Sekhri N, Zaman MJ, Hemingway H, Feder GS, Timmis AD. Atypical chest pain in patients with suspected stable angina: impact on diagnosis and coronary outcomes. Eur Heart J Qual Care Clin Outcomes 2015;1:37–43.

7. Halbert RJ, Isonaka S, George D, Iqbal A. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003;123:1684–1692.

8. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2013. www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf.

9. Barnes PJ. Chronic obstructive pulmonary disease: effects beyond the lungs. Plast Reconstr Surg 2010;126:40020.

10. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010;65:95–96.

11. Rathnie KJ, Yan R, Smeeht L, Quint JK. Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMJ Open 2015;5:e007624.

12. Maclay JD, MacNee W. Cardiovascular disease in COPD. Eur Respir J 2003;22:382–390.

13. Hadi HAR, Zubaid M, Mahmeed WA, El-Menyar AA, Ridha M, Alsheikh-Ali AA, Singh R, Assad N, Habbib KA, Suwaidi JA. Prevalence and prognosis of chronic obstructive pulmonary disease among 8167 middle eastern patients with acute coronary syndrome. Clin Cardiol 2010;33:228–235.

14. Andell P, Zambali MA, Mahtem HA, Al-Menyar AA, Rashid M, Alsheikh-Ali AA, Singh R, Assad N, Habbib KA, Suwaidi JA. Prevalence and prognosis of chronic obstructive pulmonary disease among 8167 middle eastern patients with acute coronary syndrome. Eur J Cardiol 2010;43:334–337.

15. Hadi HAR, Zubaid M, Mahmeed WA, El-Menyar AA, Ridha M, Alsheikh-Ali AA, Singh R, Assad N, Habbib KA, Suwaidi JA. Prevalence and prognosis of chronic obstructive pulmonary disease among 8167 middle eastern patients with acute coronary syndrome. Eur J Cardiol 2010;33:228–235.

16. Andell P, Koul S, Martinsson A, Sundström J, Jernberg T, Smith JG, James S, Gulba D, Hambrecht R, Herrmann J, Kastrati A, Kjeldsen K, Kristensen SD, Bertrand M, Bøtker HE, Collet J-P, Crea F, Danchin N, Falk E, Goudevenos J, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Lancellotti P, Mehilli J, Merkely B, Montalescot G, Neumann F-J, Neyses L, Perk J, Roffi M, Romeo F, Ruda M, Swahn E, Valgimigli M, Vrints CJ, Widimsky P, Arosh M, Chiller V, Courtin M, de la Lande M, Jagielo A, O’Loughlin J, Paradis G, Rinfret S, Sarrafzadegan N, Sharma S, Lawson C, Yadav R, Pilotte L. Burden of smoking in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial. J Am Coll Cardiol 2013;61:524–532.

Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:3999–3054.

25. National Institute for Health and Care Excellence. Unstable angina and NSTEMI: the early management, 2010. www.nice.org.uk/guidance/cg34/resource/unstable-angina-and-nstemi-early-management-975749355205.

26. Bhatt DL, Roe MT, Peterson ED, Li Y, Chen YJ, Harrington RA, Greenbaum AB, Berger PB, Cannon CP, Cohen DJ, Gibson CM, Sacco JD, Kleiman NS, Hochman JS, Boden WE, Brindis RG, Peacock WF, Smith SC Jr, Pollack CV Jr, Gibler WB, Ohman EM. CRUSADE Investigators. Utilization of early invasive management strategies for high-risk patients with non–ST-segment elevation acute myocardial infarction: results from the crusade quality improvement initiative. JAMA 2004;292:2096–2104.

27. Collinsen J, Flather MD, Fox KAA, Findlay I, Rodrigues E, Dooley P, Ludman P, Adgey J, Bowler TJ, Mattu R. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: prospective Registry of Acute Ischaemic Syndromes in the UK (RAIS-UK). Eur Heart J 2000;21:1450–1457.

28. Collinsen J, Floster TM, Salpeter EE, Poole PJ, Cates CJ. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med 2003;97:1094–1101.

29. Raposeiras Roubin S, Abu Assi E, Alvarez Alvarez B, Cambeiro Gonzalez C, Castainera M, Bouzas N, Grand A, Fandino Vaquero R, Pena Gil C, Gonzalez-Juanatey JR. In-hospital and follow-up mortality associated to chronic obstructive pulmonary disease in a contemporary cohort of patients with acute coronary syndrome. Eur Heart J 2012;33:1084–1091.

30. Dziewierz A, Sudak Z, Rakowski T, Brzezinski M, Zdziennick J, Mielecki W, Dubiel D. Relationship between chronic obstructive pulmonary disease and in-hospital management and outcomes in patients with acute myocardial infarction. Kardiol Pol 2010;66:294–301.

31. Kjeller E, Kaber L, Iversen K, Torp-Pedersen C, on behalf of the Trace Study Group. Importance of chronic obstructive pulmonary disease for prognosis and diagnosis of congestive heart failure in patients with acute myocardial infarction. Eur J Heart Fail 2004;6:71–77.

32. Quint JK, Herrrett E, Timmis A, Hemingway H, Smeeth L. Survival after the first myocardial infarction is shorter in patients with COPD compared to the general population. Thorax 2011;66:A45–A46.

33. Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, Swedberg K, Pfeffer MA, McMurray JJV, Maggioni AP, for the Valsartan in Acute Myocardial Infarction Trial I. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial I (VALIANT). Eur J Heart Fail 2009;11:292–298.

34. Canto JG, Shlipak MG, Rogers WJ, Malmgren JA, Pedersen R, Morrow DA, Ornato JP, Barron HV, Kiefie C. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. JAMA 2003;290:3233–3239.

35. Bengtsson B, Eagle KA, Goodman SG, Steg PG, Budaj A, White K, Montalescot G. Acute coronary syndromes without chest pain, an underdiagnosed and under-treated high-risk group: insights from the global registry of acute coronary events. Circulation 2004;110:146–149.

36. Schneider C, Bothner U, Jick SS, Meier CR. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol 2010;25:253–260.

37. Wedzicha JA, Bril B, Allinson JP, Donaldson GC. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med 2013;11:181.

38. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010;137:1091–1097.

39. Halpin DG, Decramer M, Celli B, Kesten S, Leimer I, Tashkin D. Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT trial. Lung 2011;189:261–268.

40. Gerber Y, Rosen LJ, Goldbourt U, Benyamini Y, Drory Y. Smoking status and long-term survival after first acute myocardial infarction: a population-based cohort study. J Am Coll Cardiol 2009;54:2382–2387.

41. Katz DA, Tang F, Fasani B, Horwitz PA, Jones P, Spern J. Prevalence and correlates of smoking cessation pharmacotherapy in hospitalized smokers with acute myocardial infarction. Am Heart J 2011;161:74–80.

42. Connerney J, Grand M, Friedline A, O’Loughlin J, Paradis G, Rinfret S, Sarrafzadegan N, Sharma S, Lawson C, Yadav R, Pilotte L. Burp Opposing for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial. J Am Coll Cardiol 2013;61:524–532.
43. Quint JK, Herrett E, Bhaskaran K, Timmis A, Hemingway H, Wedzicha JA, Smeeth L. Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ 2013;347:f6650.

44. Yan AT, Yan RT, Tan M, Fung A, Cohen EA, Fitchett DH, Langer A, Goodman SG; Canadian Acute Coronary Syndromes 1 and 2 Registry Investigators. Management patterns in relation to risk stratification among patients with non-ST elevation acute coronary syndromes. Arch Intern Med 2007;167:1009–1016.

45. Rothnie K, Smeeth L, Herrett E, Pearce N, Hemingway H, Wedzicha J, Timmis A, Quint J. GRACE scores in COPD patients with acute coronary syndromes: performance and impact on secondary prevention. Eur Respir J 2015;46(Suppl. 59).